MedTrace Logo

Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013

NCT07499908 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-04-13

No results posted yet for this study

Summary

This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers

Conditions

  • Healthy Adult

Interventions

DRUG

CIT-013 high dose

CIT-013

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Citryll BV

    lead INDUSTRY

Principal Investigators

  • Maarten Kraan · Citryll BV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2026-08-15
Completion
2026-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07499908 on ClinicalTrials.gov